Tak Jihoon, Kim Yun Seok, Kim Sang Geon
College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University-Seoul, Goyang, Korea.
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul, Korea.
Clin Mol Hepatol. 2025 Jan;31(1):1-31. doi: 10.3350/cmh.2024.0441. Epub 2024 Oct 2.
The prevalence of drug-induced liver injury (DILI) and viral liver infections presents significant challenges in modern healthcare and contributes to considerable morbidity and mortality worldwide. Concurrently, metabolic dysfunctionassociated steatotic liver disease (MASLD) has emerged as a major public health concern, reflecting the increasing rates of obesity and leading to more severe complications such as fibrosis and hepatocellular carcinoma. X-box binding protein 1 (XBP1) is a distinct transcription factor with a basic-region leucine zipper structure, whose activity is regulated by alternative splicing in response to disruptions in endoplasmic reticulum (ER) homeostasis and the unfolded protein response (UPR) activation. XBP1 interacts with a key signaling component of the highly conserved UPR and is critical in determining cell fate when responding to ER stress in liver diseases. This review aims to elucidate the emerging roles and molecular mechanisms of XBP1 in liver pathogenesis, focusing on its involvement in DILI, viral liver infections, MASLD, fibrosis/cirrhosis, and liver cancer. Understanding the multifaceted functions of XBP1 in these liver diseases offers insights into potential therapeutic strategies to restore ER homeostasis and mitigate liver damage.
药物性肝损伤(DILI)和病毒性肝脏感染的流行在现代医疗保健中构成了重大挑战,并在全球范围内导致了相当高的发病率和死亡率。与此同时,代谢功能障碍相关脂肪性肝病(MASLD)已成为一个主要的公共卫生问题,反映出肥胖率的上升,并导致诸如纤维化和肝细胞癌等更严重的并发症。X盒结合蛋白1(XBP1)是一种具有碱性区域亮氨酸拉链结构的独特转录因子,其活性通过可变剪接来调节,以应对内质网(ER)稳态的破坏和未折叠蛋白反应(UPR)的激活。XBP1与高度保守的UPR的一个关键信号成分相互作用,在肝脏疾病中应对ER应激时对决定细胞命运至关重要。本综述旨在阐明XBP1在肝脏发病机制中的新作用和分子机制,重点关注其在DILI、病毒性肝脏感染、MASLD、纤维化/肝硬化和肝癌中的作用。了解XBP1在这些肝脏疾病中的多方面功能,有助于深入了解恢复ER稳态和减轻肝损伤的潜在治疗策略。